Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2024

Munoz-Zuluaga CA, Heymann JJ, Solomon JP, Patel A, Siddiqui MT, Scognamiglio T, et al. Use of the Afirma Xpression Atlas for cytologically indeterminate, Afirma Genomic Sequencing Classifier suspicious thyroid nodules: Clinicopathologic analysis with postoperative molecular testing. Am J Clin Pathol. 2024;161(5):463-468.

Pakula H, Omar M, Carelli R, Pederzoli F, Fanelli GN, Pannellini T, et al. Distinct mesenchymal cell states mediate prostate cancer progression. Nat Commun. 2024;15:363.

Augello MA, Chen X, Liu D, Lin K, Hakansson A, Sjöström M, et al. Canonical AREs are tumor suppressive regulatory elements in the prostate. bioRxiv. 2024.

van Wyk AC, Lal P, J Ogunbiyi O, Kyokunda L, Hobenu F, Dial C, et al. Multinational, Multicenter Evaluation of Prostate Cancer Tissue in Sub-Saharan Africa: Challenges and Opportunities. JCO Glob Oncol. 2024;10:e2300403.

Bergom HE, Sena LA, Day A, Miller B, Miller CD, Lozada JR, et al. Divergent immune microenvironments in two tumor nodules from a patient with mismatch repair-deficient prostate cancer. NPJ Genom Med. 2024;9(1):7.

Brantley KD, Rosenberg SM, Collins LC, Ruddy KJ, Tamimi RM, Schapira L, et al. Second Primary Breast Cancer in Young Breast Cancer Survivors. JAMA Oncol. 2024;10(6):718-725.

Magro C, Tili E, Nuovo G. Disruption of the blood-brain barrier is correlated with spike endocytosis by ACE2 + endothelia in the CNS microvasculature in fatal COVID-19. . Acta Neuropathol. 2024;147(1):47.

Obidi J, Sridhar G, Dores GM, Whitaker B, Villa CH, Storch E, et al. Patterns of red blood cell utilization: Harnessing electronic health records data from the Information Standard for Blood and Transplant (ISBT) 128 system within the Biologics Effectiveness and Safety (BEST) initiative. Transfusion. 2024;64(6):998-1007.

Lacunza E, Ahuja A, Coso OA, Abba M, Ramos JC, Cesarman E, et al. Unveiling the role of KSHV-infected human mesenchymal stem cells in Kaposi's sarcoma initiation. J Med Virol. 2024;96(5):e29684.

Sumiyoshi T, Wang X, Warner EW, Sboner A, Annala M, Sigouros M, et al. Molecular features of prostate cancer after neoadjuvant therapy in the phase 3 CALGB 90203 trial. J Natl Cancer Inst. 2024;116(1):115-126.